Skip to main content
BLCO
NYSE Industrial Applications And Services

At Controlling Shareholder's Request, Bausch + Lomb Overhauls Board and Reaffirms Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$16.76
Mkt Cap
$5.986B
52W Low
$13.53
52W High
$18.915
52W Position info
24% above low
Off High info
11% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

BLCO sits 24% above its 52-week low of $13.53.

Summary

At the request of controlling shareholder Bausch Health, Bausch + Lomb replaced four directors with four new members, including Bausch Health's CEO. The company also reaffirmed its 2026 guidance and highlighted improved Q2 cash flow.


Key Events · Executive and Board Changes · BLCO

  • Board Overhaul at Controlling Shareholder's Request

    Effective August 5, 2026, four directors resigned and four new directors were appointed at the request of Bausch Health Companies Inc., which owns approximately 87% of Bausch + Lomb. Among the new appointees is Thomas J. Appio, CEO of Bausch Health.

  • Consulting Agreement with Departing Director

    Departing director Thomas W. Ross, Sr. entered a one-year consulting agreement with the company for a total fee of $400,000, payable in quarterly installments of $100,000.

  • 2026 Guidance Reaffirmed

    Full-year 2026 guidance was reaffirmed, including revenue of $5.440 billion to $5.540 billion and Adjusted EBITDA excluding Acquired IPR&D of $1.025 billion to $1.075 billion.

  • Q2 2026 Financial Highlights Disclosed

    Second-quarter revenue reached $1.394 billion (+9% YoY), with net cash from operations of $153 million and adjusted cash flow from operations of $161 million—both significantly improved from Q1 2026.


Analysis · BLCO · Industrial Applications And Services

At the request of Bausch Health, its 87% controlling shareholder, Bausch + Lomb replaced four directors with four new appointees, including Bausch Health's CEO—a move that signals tighter alignment with the parent. The company also reaffirmed its recently raised 2026 guidance and disclosed strong Q2 cash flow, which may cushion any governance concerns. While the board shake-up is a material governance event, the reaffirmed outlook and the absence of disagreement among departing directors limit the negative impact.

At the time of this filing, BLCO was trading at $16.76 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $6B. The 52-week trading range was $13.53 to $18.92. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BLCO - Latest Insights

BLCO
Jul 29, 2026, 4:17 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $16.20
Real-time Price: $16.76 info
Change: +$0.560 (+3%) info
Market Cap: $5.986B info
BLCO
Jul 29, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $16.61
Real-time Price: $16.76 info
Change: +$0.150 (+0.90%) info
Market Cap: $5.986B info
BLCO
Apr 29, 2026, 4:36 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $15.50
Real-time Price: $16.76 info
Change: +$1.26 (+8%) info
Market Cap: $5.986B info
BLCO
Apr 29, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.72
Real-time Price: $16.76 info
Change: +$1.04 (+7%) info
Market Cap: $5.986B info
BLCO
Apr 10, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $16.49
Real-time Price: $16.76 info
Change: +$0.270 (+2%) info
Market Cap: $5.986B info